Kyntra Bio, Inc. (KYNB)Healthcare | Biotechnology | San Francisco, United States | NasdaqGS
7.32 USD
+0.13
(1.808%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 7.32 Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:09 p.m. EDT
Despite an analyst upgrade and a bull call target of $43, KYNB is fundamentally compromised: classification as 'Biotechnology' with negative gross margins (28.48% profit margin contradicted by negative gross margin and negative book value) suggests a misclassification or distressed state, combined with -59% revenue growth and flat/low volume. The short-term forecast model predicts a -5.1% price decline over 45 days, indicating a bearish technical bias that outweighs the optimistic news headline. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.124861 |
| MSTL | 0.140105 |
| AutoETS | 0.147021 |
| AutoARIMA | 0.212956 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 49% |
| H-stat | 4.13 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.169 |
| Excess Kurtosis | 0.42 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 437.095 |
| Revenue per Share | 1.593 |
| Market Cap | 29,622,774 |
| Forward P/E | -0.71 |
| Beta | 0.90 |
| Profit Margins | 2848.63% |
| Previous Name | FibroGen, Inc. |
| Website | https://www.kyntrabio.com |
As of April 18, 2026, 10:09 p.m. EDT: Options data is absent (empty objects for calls and puts), precluding a direct analysis of speculator positioning or unusual flow. However, implied volatility cannot be assessed without price-based options data, and the lack of flow data correlates with the extremely low trading volume (4,099) relative to the 32-day average, suggesting a lack of active market interest or liquidity.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.020209074 |
| Address1 | 350 Bay Street |
| Address2 | Suite 100 #6009 |
| All Time High | 1,713.75 |
| All Time Low | 4.5 |
| Ask | 7.29 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 13,500 |
| Average Daily Volume3 Month | 32,319 |
| Average Volume | 32,319 |
| Average Volume10Days | 13,500 |
| Beta | 0.903 |
| Bid | 7.1 |
| Bid Size | 1 |
| Book Value | -7.423 |
| City | San Francisco |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.32 |
| Current Ratio | 3.388 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 7.39 |
| Day Low | 7.2 |
| Debt To Equity | 437.095 |
| Display Name | Kyntra Bio |
| Earnings Call Timestamp End | 1,773,694,800 |
| Earnings Call Timestamp Start | 1,773,694,800 |
| Earnings Timestamp | 1,773,691,200 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | -44,594,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.118 |
| Enterprise To Revenue | -0.82 |
| Enterprise Value | -5,282,226 |
| Eps Current Year | -13.54 |
| Eps Forward | -10.25 |
| Eps Trailing Twelve Months | -14.4 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 415 978 1902 |
| Fifty Day Average | 7.2105 |
| Fifty Day Average Change | 0.10950041 |
| Fifty Day Average Change Percent | 0.015186244 |
| Fifty Two Week Change Percent | 2.0209074 |
| Fifty Two Week High | 12.6 |
| Fifty Two Week High Change | -5.28 |
| Fifty Two Week High Change Percent | -0.41904762 |
| Fifty Two Week Low | 4.85 |
| Fifty Two Week Low Change | 2.4700003 |
| Fifty Two Week Low Change Percent | 0.5092784 |
| Fifty Two Week Range | 4.85 - 12.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,415,975,400,000 |
| Float Shares | 3,562,665 |
| Forward Eps | -10.25 |
| Forward P E | -0.7141464 |
| Free Cashflow | 5,109,875 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 34 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -2.73804 |
| Gross Profits | -17,633,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01566 |
| Held Percent Institutions | 0.28449 |
| Implied Shares Outstanding | 4,046,827 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,750,118,400 |
| Last Split Factor | 1:25 |
| Long Business Summary | Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. |
| Long Name | Kyntra Bio, Inc. |
| Market | us_market |
| Market Cap | 29,622,774 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_28484 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -58,204,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 29,339,495 |
| Number Of Analyst Opinions | 1 |
| Open | 7.39 |
| Operating Cashflow | -4,774,000 |
| Operating Margins | -10.58653 |
| Payout Ratio | 0.0 |
| Phone | 415 978 1200 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 7.32 |
| Post Market Time | 1,776,456,605 |
| Prev Name | FibroGen, Inc. |
| Previous Close | 7.19 |
| Price Eps Current Year | -0.5406204 |
| Price Hint | 2 |
| Price To Book | -0.9861243 |
| Price To Sales Trailing12 Months | 4.5998096 |
| Profit Margins | 28.48634 |
| Quick Ratio | 3.187 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.13 |
| Regular Market Change Percent | 1.80807 |
| Regular Market Day High | 7.39 |
| Regular Market Day Low | 7.2 |
| Regular Market Day Range | 7.2 - 7.39 |
| Regular Market Open | 7.39 |
| Regular Market Previous Close | 7.19 |
| Regular Market Price | 7.32 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 4,009 |
| Return On Assets | -0.16962999 |
| Revenue Growth | -0.593 |
| Revenue Per Share | 1.593 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 4,046,827 |
| Shares Percent Shares Out | 0.028099999 |
| Shares Short | 113,876 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 111,841 |
| Short Name | Kyntra Bio, Inc. |
| Short Percent Of Float | 0.0287 |
| Short Ratio | 3.24 |
| Source Interval | 15 |
| State | CA |
| Symbol | KYNB |
| Target High Price | 43.0 |
| Target Low Price | 43.0 |
| Target Mean Price | 43.0 |
| Target Median Price | 43.0 |
| Total Cash | 88,978,000 |
| Total Cash Per Share | 21.987 |
| Total Debt | 19,560,000 |
| Total Revenue | 6,440,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -14.4 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.9219 |
| Two Hundred Day Average Change | -1.6018996 |
| Two Hundred Day Average Change Percent | -0.17954692 |
| Type Disp | Equity |
| Volume | 4,009 |
| Website | https://www.kyntrabio.com |
| Zip | 94,133 |